Advertisement

Experientia

, Volume 33, Issue 3, pp 382–383 | Cite as

3-Amino-1-(3,4-dichloro-α-methyl-benzyl)-2-pyrazolin-5-one (Bay g 2821), a potent diuretic from a new substance class

  • E. Möller
  • H. Horstmann
  • K. Meng
  • D. Loew
Specialia

Summary

Chemistry, salidiuretic activity and mechanism of action of 3-amino-1-(3,4-dichloro-α-methyl-benzyl)-2-pyrazolin-5-one (Bay g 2821), a new diuretic, are described. Owing to the initial rapid onset of activity, the reserve in capacity and the additional long duration of activity, this substance represents a potent diuretic and antihypertensive agent.

Keywords

Antihypertensive Agent Rapid Onset Substance Class Potent Diuretic Initial Rapid Onset 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Literatur

  1. 2.
    F. C. Novello and J. M. Sprague, J. Am. Chem. Soc.79, 2028 (1957).Google Scholar
  2. 3.
    R. F. Pitts, F. Krück, R. Lozano, D. W. Taylor, O. P. A. Heidenreich and R. H. Kessler, J. Pharm. exp. Ther.123, 89 (1958).Google Scholar
  3. 4.
    W. Graf, E. Girod, E. Schmid and W. G. Stoll, Helv. chim. Acta42, 1085 (1959).Google Scholar
  4. 5.
    E. G. Stenger, H. Wirz and R. Pulver, Schweiz. med. Wschr.89, 1126 (1959).PubMedGoogle Scholar
  5. 6.
    E. Jucker, A. Lindemann, E. Schenker, E. Flückiger and M. Taeschler, Fortschr. ArzneimittForsch. (Drug Res.)13, 269 (1963).Google Scholar
  6. 7.
    E. Flückiger, W. Schalch and M. Taeschler, Schweiz. med. Wschr.93, 1232 (1963).PubMedGoogle Scholar
  7. 8.
    H. Horstmann, H. Wollweber and K. Meng, Fortschr. Arzneimitt Forsch. (Drug Res.)17, 653 (1963).Google Scholar
  8. 9.
    K. Meng and G. Kroneberg, Fortschr. ArzneimittForsch. (Drug Res.)17, 659 (1967).Google Scholar
  9. 10.
    E. M. Schultz, E. J. Cragoe, J. B. Bicking, W. A. Bolhofer and J. M. Sprague, J. med. pharm. Chem.5, 660 (1962).Google Scholar
  10. 11.
    K. H. Beyer, J. E. Baer, J. K. Michaelson and H. F. Russo, J. Pharmac. exp. Ther.147, 1 (1965).Google Scholar
  11. 12.
    W. Sturm, W. Siedel, R. Weyer and H. Ruschig, Chem. Ber.99, 328 (1966).Google Scholar
  12. 13.
    R. Muschaweck and P. Hajdú, Fortschr. ArzneimittForsch.14, 44 (1964).Google Scholar
  13. 14.
    P. W. Feit, J. med. Chem.14, 432 (1971).PubMedGoogle Scholar
  14. 15.
    E. H. Østergaard, M. P. Magnussen, Chr. Kaergaard-Nielsen, E. Eilertsen and H.-H. Frey, Fortschr. ArzneimittForsch. (Drug Res.)22, 66 (1972).Google Scholar
  15. 16.
    H. Horstmann, K. Meng and E. Wehinger, Br. P. 1391051; Br. P. 1391052.Google Scholar
  16. 17.
    E. Möller, K. Meng, E. Wehinger and H. Horstmann, Br. P. 1429141; Br. P. 1434171.Google Scholar
  17. 18.
    A. Weissberger, H. D. Porter and W. A. Gregory, J. Am. Chem. Soc.66, 1851 (1944).Google Scholar
  18. 19.
    L. Born, in preparation.Google Scholar
  19. 20.
    K. Meng, D. Loew, K. Stoepel and F. Hoffmeister, Pharmatherapeutica, in press.Google Scholar
  20. 21.
    D. Loew and K. Meng, Pharmatherapeutica1, 333 (1977).Google Scholar

Copyright information

© Birkhäuser Verlag 1977

Authors and Affiliations

  • E. Möller
    • 1
  • H. Horstmann
    • 1
  • K. Meng
    • 1
  • D. Loew
    • 1
  1. 1.Pharma-ForschungszentrumBayer AGWupperta(BRD)

Personalised recommendations